Correction of Huntington’s Disease Phenotype by Genistein-Induced Autophagy in the Cellular Model

NeuroMolecular Medicine

Volumn 20, Issue 1, 2018, Pages 112-123

  Pierzynowska, Karolina ^a   Gaffke, Lidia ^a   Hać, Aleksandra ^a   Mantej, Jagoda ^a   Niedziałek, Natalia ^a   Brokowska, Joanna ^a   Węgrzyn, Grzegorz ^a  

^a UNIVERSITY OF GDA SK   (Poland)

Author keywords

Autophagy; Genistein; Huntington s disease; Protein aggregates

Indexed keywords

CELL MARKER; CHLOROQUINE; GENISTEIN; HUNTINGTIN; LC3 II PROTEIN; UNCLASSIFIED DRUG; FUSION PROTEIN; HTT PROTEIN, HUMAN;

ALLELE; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EMBRYO; EXON; GENE PRODUCT; GENETIC TRANSFECTION; HEK293 CELL LINE; HTT GENE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; LYSOSOME; MTT ASSAY; MUTANT; PLASMID; PRIORITY JOURNAL; UPREGULATION; WILD TYPE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; PROTEINOSIS; REPORTER GENE;

AUTOPHAGY; CHLOROQUINE; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; GENISTEIN; HEK293 CELLS; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; LYSOSOMES; PROTEIN AGGREGATION, PATHOLOGICAL; RECOMBINANT FUSION PROTEINS;

EID: 85041896195     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-018-8482-1     Document Type: Article

References (38)

1. Aronin, N., & DiFiglia, M. (2014). Huntingtin-lowering strategies in Huntington’s disease: Antisense oligonucleotides, small RNAs, and gene editing. Movement Disorders, 29, 1455–1461.
2. Bañez-Coronel, M., Ayhan, F., Tarabochia, A. D., Zu, T., Perez, B. A., Tusi, S. K., et al. (2015). RAN translation in Huntington disease. Neuron, 88, 667–677.
3. Bennett, E. J., Shaler, T. A., Woodman, B., Ryu, K. Y., Zaitseva, T. S., Becker, C. H., et al. (2007). Global changes to the ubiquitin system in Huntington’s disease. Nature, 448, 704–708.
4. Bhutani, N., Venkatraman, P., & Goldberg, A. L. (2007). Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polyglutamine sequences released by proteasomes during protein degradation. EMBO Journal, 26, 1385–1396.
5. de Ruijter, J., Valstar, M. J., Narajczyk, M., Wegrzyn, G., Kulik, W., Ijlst, L., et al. (2012). Genistein in Sanfilippo disease: A randomized controlled crossover trial. Annals of Neurology, 71, 110–120.
6. Finkbeiner, S., & Mitra, S. (2008). The ubiquitin-proteasome pathway in Huntington’s disease. Scientific World Journal, 8, 421–433.
7. Galka-Marciniak, P., Urbanek, M. O., & Krzyzosiak, W. J. (2012). Triplet repeats in transcripts: Structural insights into RNA toxicity. Biological Chemistry, 393, 1299–1315.
8. Gil, J. M., & Rego, A. C. (2008). Mechanisms of neurodegeneration on Huntington’s disease. European Journal of Neuroscience, 27, 2803–2820.
9. Goloubinoff, P. (2016). Mechanisms of protein homeostasis in health, aging and disease. Swiss Medical Weekly, 146, w14306.
10. Gros, F., & Muller, S. (2014). Pharmacological regulators of autophagy and their link with modulators of lupus disease. British Journal of Pharmacology, 171, 4337–4359.
11. Haas, L. T., Kostylev, M. A., & Strittmatter, S. M. (2014). Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5). Journal of Biological Chemistry, 289, 22477–28460.
12. Jakóbkiewicz-Banecka, J., Piotrowska, E., Narajczyk, M., Barańska, S., & Wegrzyn, G. (2009). Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. Journal of Biomedical Science, 16, 26.
13. Jana, N. R., Zemskov, E. A., Wang, G., & Nukina, N. (2001). Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Human Molecular Genetics, 10, 1049–1059.
14. Kim, K. H., Dodsworth, C., Paras, A., & Burton, B. K. (2013). High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system. Molecular Genetics and Metabolism, 109, 382–385.
15. Lecca, D., Nevin, D. K., Mulas, G., Casu, M. A., Diana, A., Rossi, D., et al. (2015). Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice. Neuroscience, 302, 23–35.
16. Malinowska, M., Wilkinson, F. L., Bennett, W., Langford-Smith, K. J., O’Leary, H. A., Jakobkiewicz-Banecka, J., et al. (2009). Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Molecular Genetics and Metabolism, 98, 235–242.
17. Malinowska, M., Wilkinson, F. L., Langford-Smith, K. J., Langford-Smith, A., Brown, J. R., Crawford, B. E., et al. (2010). Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS ONE, 5, e14192.
18. Menze, E. T., Esmat, A., Tadros, M. G., Abdel-Naim, A. B., & Khalifa, A. E. (2015). Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: Impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties. PLoS ONE, 10, e0117223.
19. Menze, E. T., Esmat, A., Tadros, M. G., Khalifa, A. E., & Abdel-Naim, A. B. (2016). Genistein improves sensorimotor gating: Mechanisms related to its neuroprotective effects on the striatum. Neuropharmacology, 105, 35–46.
20. Mizushima, N., Yoshimori, T., & Levine, B. (2010). Methods in mammalian autophagy research. Cell, 140, 313–326.
21. Morreale, M. K. (2015). Huntington’s disease: Looking beyond the movement disorder. Advances in Psychosomatic Medicine, 34, 135–142.
22. Moskot, M., Jakóbkiewicz-Banecka, J., Kloska, A., Smolińska, E., Mozolewski, P., Malinowska, M., et al. (2015a). Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids. Sci Rep, 5, 9378.
23. Moskot, M., Jakóbkiewicz-Banecka, J., Smolińska, E., Piotrowska, E., Węgrzyn, G., & Gabig-Cimińska, M. (2015b). Effects of flavonoids on expression of genes involved in cell cycle regulation and DNA replication in human fibroblasts. Molecular and Cellular Biochemistry, 407, 97–109.
24. Moskot, M., Montefusco, S., Jakóbkiewicz-Banecka, J., Mozolewski, P., Węgrzyn, A., Di Bernardo, D., et al. (2014). The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activation. Journal of Biological Chemistry, 289, 17054–17069.
25. Petrosino, S., Ahmad, A., Marcolongo, G., Esposito, E., Allarà, M., Verde, R., et al. (2015). Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain. Pharmacological Research, 91, 9–14.
26. Piotrowska, E., Jakóbkiewicz-Banecka, J., Barańska, S., Tylki-Szymańska, A., Czartoryska, B., Wegrzyn, A., et al. (2006). Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. European Journal of Human Genetics, 14, 846–852.
27. Pritchard, C., Mayers, A., & Baldwin, D. (2013). Changing patterns of neurological mortality in the 10 major developed countries—1979–2010. Public Health, 2013(127), 357–368.
28. Pryor, W. M., Biagioli, M., Shahani, N., Swarnkar, S., Huang, W. C., Page, D. T., et al. (2014). Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington’s disease. Science Signal, 7, ra103.
29. Ratovitski, T., Arbez, N., Stewart, J. C., Chighladze, E., & Ross, C. A. (2015). PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant Huntingtin and is impaired in Huntington’s disease (HD). Cell Cycle, 14, 1716–1729.
30. Ravikumar, B., Duden, R., & Rubinsztein, D. C. (2002). Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Human Molecular Genetics, 11, 1107–1117.
31. Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., et al. (2004). Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature Genetics, 36, 585–595.
32. Sameni, S., Syed, A., Marsh, J. L., & Digman, M. A. (2016). The phasor-FLIM fingerprints reveal shifts from OXPHOS to enhanced glycolysis in Huntington disease. Scientific Reports, 6, 34755.
33. Shannon, K. M., & Fraint, A. (2015). Therapeutic advances in Huntington’s disease. Movement Disorders, 30, 1539–1546.
34. Tasdemir, E., Galluzzi, L., Maiuri, M. C., Criollo, A., Vitale, I., Hangen, E., et al. (2008). Methods for assessing autophagy and autophagic cell death. Methods in Molecular Biology, 445, 29–76.
35. Tsai, T. H. (2005). Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. Journal of Chromatography A, 1073, 317–322.
36. Wegrzyn, G., Jakóbkiewicz-Banecka, J., Gabig-Cimińska, M., Piotrowska, E., Narajczyk, M., Kloska, A., et al. (2010). Genistein: A natural isoflavone with a potential for treatment of genetic diseases. Biochemical Society Transactions, 38, 695–701.
37. Yang, Y. P., Hu, L. F., Zheng, H. F., Mao, C. J., Hu, W. D., Xiong, K. P., et al. (2013). Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacologica Sinica, 34, 625–635.
38. Zhao, T., Hong, Y., Li, X. J., & Li, S. H. (2016). Subcellular clearance and accumulation of Huntington disease protein: A mini-review. Frontiers in Molecular Neuroscience, 9, 27.